Merck LLY-284

LLY-284

≥98% (HPLC)

(2R,3R,4S,5R)-2-(4-Amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((S)-hydroxy(phenyl)methyl)tetrahydrofuran-3,4-diol, LLY284, (S)-5′-phenyl-7-deazaadenosine; 6-amino-9-[(S)-5′-phenyl(ribofuranosyl)]-7-deazapurine, LLY 284

assay

≥98% (HPLC)

form

powder

색상

white to beige

저장 온도

2-8°C

SMILES string

O[C@@H]1[C@@H]([C@@H](O)C2=CC=CC=C2)O[C@@H](N3C(N=CN=C4N)=C4C=C3)[C@@H]1O

LLY-284 is the less potent diastereomer of the potent SAM-competitive PRMT5 inhibitor LLY-283 (IC50 = 20 nM against PRMT5-catalyzed methylation of an H4R3-derived peptide substrate) and an ideal control compound for cellular studies. For characterization details of the active probe, LLY-283, please visit the LLY-283 probe summary on the Structural Genomics Consortium (SGC) website.

LLY-283, the active probe, is available from Sigma. To learn more about and purchase LLY-283, click here.

To learn about other SGC chemical probes for epigenetic targets, visit sigma.com/sgc